Drugmaker Johnson & Johnson has halted manufacturing of its single-dose COVID-19 vaccine, in line with a New York Instances report.
The pharmaceutical firm final 12 months quietly shut down manufacturing at a plant in Leiden, Netherlands, which was the one facility the place usable doses of the vaccine have been manufactured, catching a few of its prospects off guard, together with creating nations that favor the single-dose J&J drug over two-dose options, the report states.
Johnson & Johnson has as a substitute been utilizing the plant to work on an experimental and doubtlessly extra worthwhile drug that might defend in opposition to an unrelated respiratory virus, in line with the report.
The plant is anticipated to renew manufacturing of the COVID-19 vaccine, however it’s unclear when.
J&J didn’t touch upon the plant closure stories, however mentioned in an announcement to CBS Information “we presently have tens of millions of doses of our COVID-19 vaccine in stock” and “we proceed to meet our contractual obligations … [to] the African Union.”
Vaccine of alternative for poorer nations
The J&J vaccine, known as the Janssen COVID-19 vaccine, made by Janssen Biotech, a subsidiary of Johnson & Johnson, is the vaccine of alternative for poorer nations which are relying on the drugmaker to assist them combat the pandemic.
Wealthier nations just like the U.S. have favored pictures from Moderna and Pfizer, as a result of the 2 look like more practical in opposition to COVID-19 variants like Omicron, and since the Janssen vaccine has, previously, been linked to uncommon however doubtlessly life-threatening blood clots.
On condition that just one dose of the J&J vaccine is required, although, it is cheaper than its double-dose counterparts and in addition simpler to ship, making it fashionable in lower-income nations.